Drugs / SNP-612
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03868566 | Aug 2017 → Sep 2021 | metabolic dysfunction-associated steatohepatitis | Sinew Pharma Inc. | Terminated | Met primary Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNP-612 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03868566 ↗ |
| Route | Oral | “Subjects will take dose1 once a day orally for 12 weeks” NCT03868566 ↗ |